AN2728 (Atopic Dermatitis) Market 2022

Fareeq Rahal 2014-02-12

Views 39

Complete report is available http://www.rnrmarketresearch.com/an2728-atopic-dermatitis-forecast-and-market-analysis-to-2022-market-report.html .

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
Anacor is developing AN2728, a boron-containing small molecule for the potential treatment of atopic dermatitis. AN2728 inhibits phosphodiesterase 4 (PDE4) and reduces the production of TNF-a, a precursor involved in the immune response and subsequent inflammatory process seen in atopic dermatitis.

Share This Video


Download

  
Report form